Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies

Vrouyr Bilemjian, Yusheng Lin, Wei Wan, Gabriella Egri, Gerwin Huls, Thomas Heinze, Edwin Bremer, Martin Gericke*, Lars Dähne*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Downloads (Pure)


An efficient and easy-to-use approach is presented for obtaining biocompatible polysaccharide-based nanoparticles (NP) that can act as tumor-specific drug delivery agents. Two antibodies are directly immobilized onto reactive xylan phenyl carbonate (XPC) NP; namely Cetuximab (CTX) that binds to human epidermal growth factor receptor (EGFR) and Atezolizumab (ATZ) that binds to programmed death-ligand 1 (PD-L1). High coupling efficiency (up to 100%) are achieved without any pre-activation and no aggregation occurs during antibody immobilization. By quartz crystal microbalance experiments with dissipation monitoring (QCM-D), flow cytometry assays, and confocal laser scanning microscopy imaging it is demonstrated that the functionalized XPC-NP specifically bind to cells carrying the corresponding antigens. Moreover, the NP retain the antibody specific bioactivities (growth inhibition for CTX and induction of T-cell cytotoxicity for ATZ).

Original languageEnglish
Article numbere202300828
Number of pages12
Issue number5
Early online date18-Jan-2024
Publication statusPublished - 1-Mar-2024


  • polysaccharide-based nanoparticles
  • xylan phenyl carbonate
  • antibody functionalization
  • tumor-targeting
  • cetuximab
  • atezolizumab

Cite this